Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00253409
Other study ID # CDR0000448615
Secondary ID ICR-CTSU-MARSEU-
Status Active, not recruiting
Phase N/A
First received November 11, 2005
Last updated July 11, 2009
Start date May 2005

Study information

Verified date July 2009
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy before surgery may shrink the tumor so that it can be removed. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether combination chemotherapy is more effective with or without surgery and radiation therapy in treating mesothelioma.

PURPOSE: This randomized clinical trial is studying combination chemotherapy, surgery, and radiation therapy to see how well they work compared to combination chemotherapy alone in treating patients with mesothelioma that can be removed by surgery.


Description:

OBJECTIVES:

- Compare the feasibility of neoadjuvant combination chemotherapy with vs without surgery and adjuvant radiotherapy in patients with resectable malignant mesothelioma.

- Compare the overall survival of patients treated with these regimens.

- Compare the quality of life of patients treated with these regimens.

OUTLINE: This is a multicenter, pilot study followed by a randomized, controlled study.

Patients undergo 3 courses of a platinum-based (cisplatin or carboplatin) combination chemotherapy regimen to be determined by the treatment center. Upon completion of combination chemotherapy, patients are randomized to 1 of 2 treatment arms provided tumor is resectable and there is no disease progression.

- Arm I: Patients undergo extra-pleural pneumonectomy followed by post-operative radiotherapy.

- Arm II: Patients undergo follow-up only. Patients may receive additional standard therapy according to their treatment center.

Quality of life is assessed at baseline, every 3 months for 1 year, every 6 months for 1 year, and then annually thereafter.

After completion of study treatment, patients are followed periodically for 2 years and then annually thereafter.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 50-670 patients will be accrued for this study.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 670
Est. completion date
Est. primary completion date June 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically and immuno-histochemically confirmed malignant mesothelioma

- Resectable disease (T1-3, N0-1, M0) with no distant metastases

- Eligible to undergo extra-pleural pneumonectomy based on British Thoracic Society guidelines

PATIENT CHARACTERISTICS:

Performance status

- WHO 0-1

Life expectancy

- Not specified

Hematopoietic

- Not specified

Hepatic

- Not specified

Renal

- Normal renal function

Cardiovascular

- Ejection fraction = 40%

Pulmonary

- Predicted post-operative FEV_1 = 40%

- Predicted post-operative DLCO = 40%

- No significant pulmonary hypertension

Other

- No physical or personal condition that would preclude ability to undergo chemotherapy or post-operative radiotherapy

- No physical or personal condition that would preclude ability to comply with follow-up requirements

PRIOR CONCURRENT THERAPY:

- Not specified

Study Design

Allocation: Randomized, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
chemotherapy

Procedure:
adjuvant therapy

conventional surgery

neoadjuvant therapy

Radiation:
radiation therapy


Locations

Country Name City State
United Kingdom Birmingham Heartlands Hospital Birmingham England
United Kingdom Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust Birmingham England
United Kingdom Bristol Royal Infirmary Bristol England
United Kingdom Queen's Hospital Burton-upon-Trent England
United Kingdom Addenbrooke's Hospital Cambridge England
United Kingdom Papworth Hospital Cambridge England
United Kingdom Ipswich Hospital Ipswich England
United Kingdom Cookridge Hospital Leeds England
United Kingdom Glenfield Hospital Leicester England
United Kingdom Leicester Royal Infirmary Leicester England
United Kingdom Royal Marsden - London London England
United Kingdom St. Thomas' Hospital London England
United Kingdom Nottingham City Hospital NHS Trust Nottingham England
United Kingdom Berkshire Cancer Centre at Royal Berkshire Hospital Reading England
United Kingdom Cancer Research Centre at Weston Park Hospital Sheffield England
United Kingdom Institute of Cancer Research - Sutton Sutton England
United Kingdom Royal Marsden - Surrey Sutton England

Sponsors (1)

Lead Sponsor Collaborator
Institute of Cancer Research, United Kingdom

Country where clinical trial is conducted

United Kingdom, 

See also
  Status Clinical Trial Phase
Recruiting NCT06057935 - A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma Phase 2
Completed NCT00075699 - Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma Phase 3
Completed NCT00821860 - Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma Phase 3
Completed NCT00004033 - Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma Phase 2
Active, not recruiting NCT03678350 - Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery Phase 1
Recruiting NCT02580747 - Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso Phase 1
Completed NCT00398138 - Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma Phase 1
Completed NCT00019825 - Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura Phase 1
Terminated NCT00898547 - Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107
Active, not recruiting NCT00030459 - Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma Phase 2
Completed NCT00004183 - Capecitabine in Treating Patients With Malignant Mesothelioma Phase 2
Completed NCT00004254 - Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed Phase 2
Completed NCT00005636 - Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery Phase 3
Completed NCT00004920 - Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura Phase 3
Completed NCT00334594 - Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma Phase 2
Completed NCT01291420 - Dendritic Cell Vaccination for Patients With Solid Tumors Phase 1/Phase 2
Recruiting NCT03852823 - Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours Phase 1
Active, not recruiting NCT01649024 - A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma Phase 2
Completed NCT00372840 - Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer N/A
Completed NCT00513877 - Bortezomib in Treating Patients With Malignant Pleural Mesothelioma Phase 2